– Positive topline results validated by additional analyses – Patient improvements beyond reduction of depression symptoms – Further insights into timing and circumstance of adverse events demonstrate COMP360 psilocybin therapy was generally well-tolerated London, UK – 1 December 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient…


Previous articleSilo Pharma Announces Grant of U.S. Patent For its Novel CNS Homing Peptide
Next articlePsychedelic Bulletin: MAPS’ $70m Investment Vehicle; atai’s Increased Stake in COMPASS; SSRI Psilocybin Interaction Study